Literature DB >> 29958780

Combined percutaneous radiofrequency ablation and cementoplasty for the treatment of extraspinal painful bone metastases: A prospective study.

Andrew Fares1, Mohamed H Shaaban2, Raafat M Reyad3, Ahmed S Ragab3, Mohga A Sami3.   

Abstract

INTRODUCTION: About 50% of patients with cancer develop bone metastasis mainly presenting with distressing, drug-resistant pain. AIM OF THE WORK: The study evaluated efficacy and safety of combined cementoplasty and bony radiofrequency ablation in palliation of intractable pain and disability in cancer patients with bony metastases. PATIENTS AND METHODS: The study included 30 adult patients suffering from localized bony metastases causing refractory moderate to severe pain. Radiofrequency bony ablation performed followed by cementoplasty were done under computed tomography (CT) guidance with conscious sedation and local anesthesia. Final CT check was done to ensure adequate lesion filling and to exclude any cement leakage. Pain, hemodynamic variables, and neurological status were checked for a minimum of 2 h before discharge. The patients were followed up weekly in the pain clinic. The primary outcome measures pain severity and daily opioid consumption. The secondary outcome measures were quality of life and the degree of disability, and procedure-related adverse outcomes.
RESULTS: Pain score, daily morphine consumption, and Oswestry Disability Index score decreased significantly after 1 day, and 1, 4 and 12  weeks. None of the patients had serious complications during the postoperative follow up visits. Only 4 patients (13.3%) experienced discomfort during, and few days after the procedure, 3 patients (10%) suffered from local infection, and 2 patients (6.7%) reported cement leakage.
CONCLUSION: Combined radiofrequency ablation and cementoplasty is a safe and effective pain relief modality in patients suffering from extraspinal painful bone metastases with improvement of the quality of life.
Copyright © 2018 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cementoplasty; Intractable pain; Localized bony metastases; Radiofrequency ablation

Mesh:

Substances:

Year:  2018        PMID: 29958780     DOI: 10.1016/j.jnci.2018.05.002

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  5 in total

1.  Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.

Authors:  Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu
Journal:  World J Urol       Date:  2022-10-02       Impact factor: 3.661

2.  Comparison of the postoperative pain change and spinal stenosis rate between percutaneous vertebroplasty combined with radiofrequency ablation and with 125I particle implantation in the treatment of metastatic spinal cord compression: A retrospective study.

Authors:  Yu He; Shilong Han; Chungen Wu; Fei Ge; Jianbo Wang
Journal:  J Interv Med       Date:  2021-12-23

Review 3.  Interventional Radiology in the Management of Metastases and Bone Tumors.

Authors:  Ferruccio Sgalambro; Luigi Zugaro; Federico Bruno; Pierpaolo Palumbo; Nicola Salducca; Carmine Zoccali; Antonio Barile; Carlo Masciocchi; Francesco Arrigoni
Journal:  J Clin Med       Date:  2022-06-07       Impact factor: 4.964

4.  Safety and Feasibility of Steerable Radiofrequency Ablation in Combination with Cementoplasty for the Treatment of Large Extraspinal Bone Metastases.

Authors:  Claudio Pusceddu; Davide De Francesco; Nicola Ballicu; Domiziana Santucci; Salvatore Marsico; Massimo Venturini; Davide Fior; Lorenzo Paolo Moramarco; Eliodoro Faiella
Journal:  Curr Oncol       Date:  2022-08-20       Impact factor: 3.109

Review 5.  Analgesia of percutaneous thermal ablation plus cementoplasty for cancer bone metastases.

Authors:  Yuandong Sun; Hao Zhang; Hui-Rong Xu; Jing-Zhou Liu; Jia Pan; Hui-Zhuan Zhai; Chang-Yan Lu; Xia Zhao; Ye-Qiang Chen; Lin-Lin Zhou; Jinming Yu; Jianjun Han
Journal:  J Bone Oncol       Date:  2019-11-05       Impact factor: 4.072

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.